Related Experiment Video
Updated: May 4, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
9.2K
Chemoradiotherapy response in recurrent rectal cancer
Stanley K T Yu1, Aneel Bhangu, Diana M Tait
1Radiotherapy Department, Royal Marsden NHS Foundation Trust, Sutton, London, UK.
Cancer Medicine
|January 10, 2014
Summary
Preoperative chemoradiotherapy (CRT) shows less tumor size reduction in recurrent rectal cancer than primary. A >50% size reduction is crucial for survival benefit in both primary and recurrent rectal cancers.
Area of Science:
- Oncology
- Radiotherapy
- Surgical Oncology
Background:
- Preoperative chemoradiotherapy (CRT) is standard for rectal cancer.
- Response to CRT in recurrent rectal cancer is less understood than in primary rectal cancer.
Purpose of the Study:
- Compare radiological tumor downsizing after CRT in primary versus recurrent rectal cancer.
- Identify optimal tumor size reduction thresholds for predicting survival outcomes.
Main Methods:
- Analyzed 385 patients (286 primary, 99 recurrent rectal cancer) undergoing CRT.
- Compared proportional tumor length change using t-tests.
- Assessed overall survival (OS) using Kaplan-Meier analysis at 30%, 40%, and 50% size reduction thresholds (RECIST).
Main Results:
- Primary rectal tumors showed significantly greater size reduction (33%) than recurrent tumors (11%) post-CRT (P < 0.01).
- No OS difference was seen with ≤30% or ≤40% size reduction.
- A >50% size reduction significantly improved 3-year OS in both groups (primary: 99% vs 77%; recurrent: 100% vs 42%).
Conclusions:
- Recurrent rectal cancer exhibits radioresistance compared to primary tumors regarding tumor size reduction post-CRT.
- A >50% tumor size reduction is a key predictor of survival benefit after CRT.
- Further research into intensified CRT for locally recurrent rectal cancer is warranted.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
927
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K